UC Berkeley’s cell therapy developer has filed for an initial public offering.

Caribou Biosciences, a US-based gene therapy developer spun out of University of California (UC) Berkeley, has filed for an initial public offering.
Founded in 2011, Caribou is using Crispr genome editing technology to develop modified cell therapies for the treatment of haematologic cancers and solid tumours.
It plans to use the IPO proceeds to fund the development of its chimeric antigen receptors (CAR) T-cell and natural killer (NK) cell therapies.
The spinout was co-founded by Jennifer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in